IL-1β Suppresses the Formation of Osteoclasts by Increasing OPG Production via an Autocrine Mechanism Involving Celecoxib-Related Prostaglandins in Chondrocytes by Watanabe, Yusuke et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2009, Article ID 308596, 9 pages
doi:10.1155/2009/308596
Research Article
IL-1β SuppressestheFormationof Osteoclastsby
IncreasingOPGProductionvia an AutocrineMechanism
Involving Celecoxib-RelatedProstaglandins inChondrocytes
Yusuke Watanabe,1 AkiNamba,1 Yukiko Aida,2,3 Kazuhiro Honda,1 Hideki Tanaka,4
Naoto Suzuki,5,6 Hideo Matsumura,2,3 andMasao Maeno4,6
1Nihon University Graduate School of Dentistry, Tokyo 101-8310, Japan
2Department of Fixed Prosthodontics, Nihon University School of Dentistry, 1-8-13, Kanda Surugadai,
Chiyoda-ku, Tokyo 101-8310, Japan
3Division of Advanced Dental Treatment, Dental Research Center, Nihon University School of Dentistry, Tokyo 101-8310, Japan
4Department of Oral Health Sciences, Nihon University School of Dentistry, Tokyo 101-8310, Japan
5Department of Biochemistry, Nihon University School of Dentistry, Tokyo 101-8310, Japan
6Division of Functional Morphology, Dental Research Center, Nihon University School of Dentistry, Tokyo 101-8310, Japan
Correspondence should be addressed to Yukiko Aida, aida@dent.nihon-u.ac.jp
Received 25 June 2009; Revised 28 August 2009; Accepted 1 December 2009
Recommended by Muzamil Ahmad
Elevated interleukin (IL)-1 concentrations in synovial ﬂuid have been implicated in joint bone and cartilage destruction.
Previously, we showed that IL-1β stimulated the expression of prostaglandin (PG) receptor EP4 via increased PGE2 production.
However, the eﬀectofIL-1β onosteoclastformationviachondrocytesisunclear. Therefore,weexamined theeﬀectofIL-1β and/or
celecoxib on the expression of macrophage colony-stimulating factor (M-CSF), receptor activator of NF-κB ligand (RANKL), and
osteoprotegerin (OPG) in human chondrocytes, and the indirect eﬀect of IL-1β on osteoclast-like cell formation using RAW264.7
cells. OPG and RANKL expression increased with IL-1β; whereas M-CSF expression decreased. Celecoxib blocked the stimulatory
eﬀe c to fI L - 1 β. Conditioned medium from IL-1β-treated chondrocytes decreased TRAP staining in RAW264.7 cells. These results
suggestthatIL-1βsuppressestheformationofosteoclast-likecellsviaincreasedOPGproductionanddecreasedM-CSFproduction
in chondrocytes, and OPG production may increase through an autocrine mechanism involving celecoxib-related PGs.
Copyright © 2009 Yusuke Watanabe et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Bone remodeling in joints involves the synthesis of bone
matrix by osteoblasts and its resorption by mature osteo-
clasts.Manycytokinesandfactors,suchasinterleukin(IL)-1,
macrophage colony-stimulating factor (M-CSF), and recep-
tor activator of NF-κB (RANK) ligand (RANKL), are known
to induce the diﬀerentiation of monocytes/macrophages
into osteoclasts; whereas osteoprotegerin (OPG), a soluble
decoy receptor for RANKL that competes with RANK for
RANKL binding, is known to suppress diﬀerentiation [1,
2]. RANKL is highly expressed on osteoblast/stromal cells,
primitive mesenchymal cells surrounding the cartilaginous
anlagen, and hypertrophying chondrocytes [3]. M-CSF and
OPG are produced and released by activated osteoblasts,
chondrocytes, and ﬁbroblasts [2, 4–6].
IL-1 plays key roles in amplifying and perpetuating
inﬂammation [7] and in the degradation of bone and carti-
lage in joints [8]. Two IL-1 subtypes have been identiﬁed: IL-
1α and IL-1β. An elevated concentration of IL-1 in the syn-
ovial ﬂuid has been implicated in joint bone and/or cartilage
destruction [9]. In addition, IL-1β is closely associated with
the expression of M-CSF, RANKL, and OPG in osteoblasts
and chondrocytes. IL-1 increases RANKL expression in
osteoblasts and chondrocytes [1, 10]. In osteoblasts, IL-
1α stimulation prompted M-CSF production [2]; whereas2 Mediators of Inﬂammation
the eﬀect of IL-1 on M-CSF expression in chondrocytes is
unclear. Conﬂicting results have been reported regarding
the eﬀect of IL-1 on OPG expression, mostly likely because
diﬀerent cells were used in each study [1, 2, 5].
We postulate that an imbalance in bone and cartilage
metabolism is responsible for arthrosis of the temporo-
mandibular joint (TMJ). Arthrosis of the TMJ is accompa-
nied by symptoms such as pain and joint sound during jaw
movement [11], and results from an imbalance between pre-
dominantly chondrocyte-controlled anabolic and catabolic
processes. It is characterized by the progressive degradation
of components of the articular cartilage extracellular matrix
and is associated with inﬂammatory factors [12–14]. Several
studies [15–18] have found elevated levels of the cytokine
IL-1β in synovial ﬂuid samples obtained from TMJ patients
with osteoarthritis, and elevated concentrations of IL-1β
in synovial ﬂuid have been implicated in joint cartilage
destruction. For these reasons, we attempted to clarify the
eﬀect of IL-1β on chondrocyte function.
Previously, we showed that IL-1α suppressed the expres-
sion of cartilage matrix proteins through suppression of the
autocrine action of bone morphogenetic protein (BMP)-2
using a human chondrosarcoma cell line, OUMS-27 [19].
We also showed that IL-1β stimulated cartilage matrix
turnover by increasing mainly matrix metalloproteinase-13
production in human chondrocytes [20]. Furthermore, IL-
1β promoted an imbalance in cartilage matrix turnover
through increased inﬂammatory cytokine production in
human chondrocytes [21]. In contrast, IL-6 and soluble IL-6
receptorappearedtosuppressthediﬀerentiationofchondro-
cytesandinducetherepairofarthrodialcartilagethroughthe
increased expression of cartilage matrix proteins, bone mor-
phogenetic protein (BMP)-7, and BMP receptors in human
chondrocytes [22]. In addition, we recently reported that
IL-1β increased the production of prostaglandin E2 (PGE2),
cyclooxygenase-2 (COX-2), and prostaglandin receptor EP4
in human chondrocytes, suggesting that IL-1β may promote
the expression of EP4 by increasing PGE2 production in
chondrocytes [23].
However, the eﬀect of IL-1β on the formation of
osteoclastsviachondrocytesremainsunclear.Forthisreason,
we examined the eﬀects of IL-1β and celecoxib, a speciﬁc
inhibitor of COX-2 [24, 25], on the expression of M-CSF,
RANKL, and OPG in human chondrocytes, and the indirect
eﬀect of IL-1β on the formation of osteoclast-like cells using
RAW264.7 cells as osteoclast precursors.
2. MaterialsandMethods Real-Time PCR
Chondrocytes were incubated in DMEM containing 10%
(v/v) FBS with 0, 10, or 100U/mL IL-1β, with or without
1μM celecoxib for up to 28 days. Total RNA was isolated
from the cells on days 1, 7, 14, 21, and 28 using an RNeasy
Mini Kit (QIAGEN, Valencia, CA, USA). The mRNA levels
were normalized using a human β-actin competitive PCR
kit (TaKaRa Bio, Shiga, Japan). The mRNA was converted
into cDNA using a RNA PCR kit (GeneAmp; Perkin-Elmer,
Branchburg, NJ, USA).
Table 1: PCR primers used in the experiments.
Target Primer sequence (5 –3 )G e n B a n k A c c .
RANKL TGCCAGTGGGAGATGTTAGAC NM 03012.2
CCTTCAATTGCGCTAGATGAC
M-CSF TAGCCACATGATTGGGAGTGGA NM 172212.1
CTCAAATGTAATTTGGCACGAGGTC
OPG AGCTGCAGTACGTCAAGCAGGA NM 002546.3
TTTGCAAACTGTATTTCGCTCTGG
GAPDH GCACCGTCAAGGCTGAGAAC NM 001725661.1
ATGGTGGTGAAGACGCCAGT
The cDNA mixtures were diluted 1:5 in sterile distilled
water, and 2-μL aliquots were subjected to real-time PCR
using SYBR Green I dye (BioWhittaker Molecular Applica-
tions, Rockland, ME, USA) in 25-μl reactions containing
1× R-PCR buﬀer, 1.5mM dNTP mixture, 1× SYBR Green
I, 15mM MgCl2, 0.25U Ex Taq (R-PCR version; TaKaRa
Bio), and 0.2μM primers (sense and antisense), as shown in
Table 1. PCR primers were designed using Primer3 software
(Whitehead Institute for Biomedical Research, Cambridge,
MA, USA). PCR was performed using a Smart Cycler
II system (Cepheid, Sunnyvale, CA, USA) with 45 cycles
of 95
◦Cf o r5 sa n d5 5
◦C for 10s; measurements were
made at the end of a 60
◦C annealing step. Data were
analyzedusingSmartCyclersoftware(version2.0d).Allreal-
time PCR experiments were performed in quadruplicate.
The calculated values for gene expression were normalized
against the levels of glyceraldehyde-3phosphate dehydroge-
nase (GAPDH) mRNA at the same time point.
2.1. Chondrocyte Cell Culture. Chondrocytes derived from
normal human femoral cartilage were obtained from Cell
Applications (San Diego, CA, USA). The cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium/nutrient
mixture F-12 (DMEM; Gibco BRL, Rockville, MD, USA)
containing 10% (v/v) fetal bovine serum (FBS; HyClone
Laboratories,Logan,UT,USA),1%(v/v)insulin-transferrin-
selenium-X supplement (Invitrogen, Carlsbad, CA, USA),
and 1% (v/v) penicillin-streptomycin solution (Sigma
Chemical, St. Louis, MO, USA) at 37
◦C in a humidiﬁed
atmosphere under 5% CO2.
For treatment with IL-1β (Genzyme/Techne, Minneapo-
lis, MN, USA), cells were seeded onto 100mm tissue culture
dishes at a density of 5 × 106 cells/cm2. After overnight
incubation, the cells were cultured for up to 28 days in
DMEM containing 10% (v/v) or 2% (v/v) FBS with 0, 10,
or 100U/mL IL-1β, with or without 1μM celecoxib (Astellas
Pharma,Tokyo,Japan).Oneunit(U)ofIL-1βcorrespondsto
the unit activity in the colorimetric MTT assay with CTLL-2
cells [26]. The IL-1β concentrations were identical to those
used in our previous studies [19–21, 23], and similar to
those found in inﬂammatory TMJ synovial ﬂuid [15]. The
celecoxib concentration used in this study was decided based
on the report of Itthipanichpong et al. [25], who examined
the blood level after injecting celecoxib, and our previous
study, which found that IL-1β increases the production ofMediators of Inﬂammation 3
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Figure 1: Eﬀect of IL-1β on RANKL gene and protein expression. (a) Cells were cultured with 0, 10, or 100U/mL IL-1β and RANKL gene
expression was determined by real-time PCR on days 1, 3, 5, 7, 10, 14, 21, and 28 of culture. (b) RANKL protein expression determined by
ELISA on days 21 and 28. Each bar indicates the mean ± SD from four separate experiments. ∗P<. 05, ∗∗P<. 01 for IL-1β treatment versus
the control.
PGE2, COX-2, and EP4 receptor in the same chondrocytes as
used in this study [23]. Celecoxib speciﬁcally inhibits COX-
2[ 24, 25]. We have already conﬁrmed that 1μM celecoxib
blocked PGE2 production by inhibiting COX-2 in 100U/mL
IL-1β-stimulated chondrocytes [23].
2.2. Enzyme-Linked Immunosorbent Assay (ELISA). Chon-
drocytes were incubated in DMEM containing 10% (v/v)
FBS with 0, 10, or 100U/mL IL-1β for 21 or 28 days. The
culturemedium was changed to DMEM containing 2% (v/v)
FBS with 0, 10, or 100U/mL IL-1β, and the cells were then
cultured for 24h at 37
◦C in a humidiﬁed atmosphere under
5% CO2.
T h el e v e l so fM - C S F ,R A N K L ,a n dO P Gp r o t e i ni n
the culture medium were determined using a commercially
available ELISA kit (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Assays were
performed in triplicate for each specimen and the data were
converted to pg/mL or ng/mL.
2.3. Tartrate-Resistant Acid Phosphatase (TRAP) Staining
of Osteoclast Precursors. Cells were cultured in DMEM
containing 10% (v/v) FBS with or without 100U/mL IL-
1β for 7 or 28 days. The culture medium was changed to
DMEMcontaining2%(v/v)FBSwithoutIL-1β,andthecells
were incubated at 37
◦C in a humidiﬁed atmosphere under
5% CO2. The culture medium was collected after 24h and
diluted with an equal volume of DMEM containing 2% (v/v)
FBS, supplemented with 50ng/mL soluble RANKL (Wako
Pure Chemical, Osaka, Japan), and then used as conditioned
medium. The RANKL concentration used was equivalent to
that used in a study examining the expression of enzymes
related to bone resorption in RAW264.7 cells [27].
To examine the diﬀerentiation of osteoclasts, we used the
murine monocyte/macrophage cell line, RAW264.7 (Dainip-
pon Pharmaceutical, Osaka, Japan). RAW264.7 cells were
plated into 96-well culture plates (6 × 103 cells/cm2)a n d
cultured in conditioned medium for 7 days. Cells cultured
withtwotypesofconditionedmedium(fromIL-1-untreated
and -treated chondrocyte growth conditions) were ﬁxed and
stained using a TRAP and alkaline phosphatase double-
staining kit (TaKaRa Bio) according to the manufacturer’s
protocol [28]o nd a y7o fc u l t u r e .T R A P - p o s i t i v em u l t i n u -
cleate cells with more than three nuclei were considered to
be osteoclast-like cells, and the data were converted into the
percentage of TRAP-positive multinucleate cells of the total
number of cells.
2.4. Statistical Analysis. All experiments were performed
in triplicate or quadruplicate. Values shown represent the
mean ±standarddeviation(SD).Signiﬁcantdiﬀerenceswere
detected using Student’s t-test with Bonferroni’s correction
or analysis of variance (ANOVA), and P-values < .05 were
considered signiﬁcant.
3. Results
3.1. RANKL Gene and Protein Expression in Chondrocytes.
In the absence of IL-1β, gene expression was unchanged
from day 1 to 21 of culture. In the presence of IL-1β,g e n e
expression increased signiﬁcantly compared to the control at
each time point (Figure 1(a)).
Consistent with the results obtained for gene expression,
RANKL protein expression was signiﬁcantly higher in the
presence of IL-1β compared to untreated control cells on
days 21 and 28 (Figure 1(b)).4 Mediators of Inﬂammation
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Figure 2: Eﬀect of IL-1β on M-CSF gene and protein expression. (a) Cells were cultured with 0, 10, or 100U/mL IL-1β and M-CSF gene
expression was determined by real-time PCR on days 1, 3, 5, 7, 10, 14, 21, and 28 of culture. (b) M-CSF protein expression determined by
ELISA on days 21 and 28. Each bar indicates the mean ± SD from four separate experiments. ∗P<. 05, ∗∗P<. 01 for IL-1β treatment versus
the control.
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Figure 3: Eﬀect of IL-1β on OPG gene and protein expression. (a) Cells were cultured with 0, 10, or 100U/mL IL-1β and OPG gene
expression was determined by real-time PCR on days 1, 3, 5, 7, 10, 14, 21, and 28 of culture. (b) OPG protein expression determined by
ELISA on days 21 and 28. Each bar indicates the mean ± SD from four separate experiments. ∗∗P<. 01 for IL-1β treatment versus the
control.
3.2. M-CSF Gene and Protein Expression in Chondrocytes.
Despite this general decreasing trend, M-CSF gene expres-
sion was consistently lower in IL-1β-treated cells compared
to the untreated control after 5 days of culture (Figure 2(a)).
Consistent with the results obtained in the gene expres-
sion study, M-CSF protein expression was signiﬁcantly lower
in the presence of IL-1β compared to untreated control cells
on days 21 and 28 (Figure 2(b)).
3.3. OPG Gene and Protein Expression in Chondrocytes.
In the absence of IL-1β, OPG gene expression decreased
gradually over 28 days. In the presence of IL-1β, OPG mRNA
expression was signiﬁcantly higher than that in control cells
at each time point (Figure 3(a)).
Consistent with the results obtained in the gene expres-
sion study, OPG protein expression was signiﬁcantly higher
in the presence of IL-1β compared to untreated control cells
on days 21 and 28 (Figure 3(b)).
3.4. Eﬀect of IL-1β and Celecoxib on RANKL, M-CSF, and
OPG Gene Expression. In the absence of IL-1β, RANKL,
M-CSF, and OPG gene expression was unaﬀected by theMediators of Inﬂammation 5
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Figure 4: Eﬀe c to fI L - 1 β and/or celecoxib on RANKL, M-CSF, and OPG gene expression. Cells were cultured with 0 or 100U/mL IL-1β,
with or without 1μM celecoxib, and RANKL, M-CSF, and OPG gene expression was determined by real-time PCR on days 21 and 28 of
culture. Each bar indicates the mean ± SD from four separate experiments. ∗P<. 05, ∗∗P<. 01 for IL-1β treatment versus the control.
presence of celecoxib. However, the presence of celecoxib
suppressed the IL-β-induced increase in RANKL and OPG
mRNA expression to control levels. In contrast, celecoxib
did not aﬀect the IL-1β-induced M-CSF gene expression on
either of the days tested (Figure 4).
3.5. TRAP Staining of Osteoclast-Like Cells. The indirect
eﬀect of IL-1β on the formation of osteoclast-like cells was
examined using TRAP staining, a diﬀerentiation marker
of osteoclasts. In this experiment, cells were cultured with
soluble RANKL and conditioned medium from 100U/mL
IL-1β-treated or untreated chondrocytes for up to 7 or 28
days. Many TRAP-positive multinucleate cells were observed
after culture with medium from IL-1β-untreated chondro-
cytes compared to cells cultured with medium from IL-
1β-treated chondrocytes (Figure 5). The number of TRAP-
positive multinucleate cells was signiﬁcantly lower when the
medium was conditioned by chondrocytes cultured with IL-
1β (Figure 6). In addition, ratio of IL-1β-treated/control was
almost the same in both on days 7 and 28 of culture: the
ratio on days 7 and 28 of culture was 0.100 and 0.098,
respectively.
4. Discussion
Cytokines released at sites of inﬂammation and infection can
alter the normal processes of cartilage turnover, resulting
in its pathological destruction or formation [29], and the
levels of inﬂammatory cytokines are higher than normal in
the synovial ﬂuid of patients with TMJ arthrosis [30, 31].
IL-1β in synovial ﬂuid not only plays a central role in the
pathophysiology of cartilage damage and degradation, but is
also associated with pain and hyperalgesia in TMJ.
Recently, we demonstrated that IL-1β increased the
production of PGE2, COX-2, and PG receptor EP4 in
human chondrocytes, suggesting that the IL-1β promotes
the expression of EP4 by an autocrine mechanism involving
increased PGE2 production in chondrocytes [23]. In light
of this ﬁnding, we hypothesized that IL-1β promotes an
imbalance in bone and cartilage matrix turnover through
an autocrine mechanism involving PGE2produced by chon-
drocytes. Therefore, we focused on the formation of osteo-
clasts via the RANK/RANKL/OPG system that commu-
nicates between osteoclast precursors and chondrocytes.
This study was performed to clarify the eﬀect of IL-
1β and/or celecoxib, a speciﬁc inhibitor of COX-2 [24,
25], on the expression of M-CSF, RANKL, and OPG in
human chondrocytes, and the indirect eﬀect of IL-1β on
the formation of osteoclast-like cells using RAW264.7 cells
as osteoclast precursors. The chondrocytes used in this
study strongly expressed type II collagen and aggrecan,
which is the common phenotype expressed by proliferating
chondrocytes and hypertrophic chondrocytes; whereas the
expression of type X collagen, which is the phenotype
expressed by hypertrophic chondrocytes, was very low in
the cells (data not shown). Therefore, we consider that
the chondrocytes used in this study were proliferating
chondrocytes.
In designing these experiments, we ﬁrst determined
an appropriate length for the culture period. In many
previous studies on M-CSF, RANKL, and OPG expression
in chondrocytes, the culture periods were brief (24h; [4, 5,
32–34]). However, because arthrosis of the TMJ typically
exhibits chronic progression, we examined gene and protein
expression in chondrocytes over a much longer culture
period of 28 days. The IL-1β concentrations used in the
current study are identical to those used in our previous6 Mediators of Inﬂammation
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Figure 5: Eﬀect of conditioned medium from IL-1β-treated and -untreated chondrocytes on the formation of osteoclast-like cells. Cells
were cultured in DMEM containing 10% FBS with or without 100U/mL IL-1β for 7 or 28 days. The culture medium was changed to DMEM
containing 2% FBS without IL-1β, and the cells were cultured for 24h. The culture medium was collected and diluted with an equal volume
of DMEM containing 2% FBS, supplemented with 50ng/mL soluble RANKL, and then used as conditioned medium. RAW264.7 cells, an
osteoclast precursor, were cultured in conditioned media from IL-1β-treated and -untreated (control) chondrocytes for up to 7 days, and
then stained using a TRAP and alkaline phosphatase double-staining kit.
studies [20, 21, 23]. The celecoxib concentration used was
identical to that used in the previous studies [23, 25].
In this study, RANKL and OPG expression increased
signiﬁcantly in cells cultured with IL-1β, whereas M-CSF
expression decreased. In addition, the level of OPG protein
was markedly higher than that of RANKL in the cells. Given
the important role of RANK, RANKL, and OPG in bone
metabolism and immune function, it has been suggested
that the RANK/RANKL/OPG system and cytokines may
work together to cause bone resorption by regulating the
RANKL/OPG ratio [35]. RANK, RANKL, and OPG mRNA
were expressed in cartilage and bone [1, 4]. Deschner
et al. [33] reported that ﬁbrochondrocytes constitutively
expressed low levels of RANKL, but high levels of OPG;
the authors reported that IL-1β upregulated the expres-
sion and synthesis of RANKL; whereas OPG expression
was unaﬀected after 4 and 24 hours. Komuro et al. [4]
reported that OPG expression in chondrocytes increased
in response to IL-1β stimulation for 24h. In osteoblasts,
RANKL expression increased after stimulation with IL-1,
IL-6, and IL-11 [1]; whereas OPG expression decreased [1,
10]. On the other hand, M-CSF expression in osteoblastsMediators of Inﬂammation 7
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cultured in DMEM containing 10% FBS with or without 100U/mL
IL-1β for 7 or 28 days. RAW264.7 cells were cultured under
the conditions described in Figure 5. TRAP-positive multinucleate
cells with more than three nuclei were considered osteoclasts,
and the data were converted to the percentage of TRAP-positive
multinucleate cells of the total number of cells. Each bar indicates
the mean ± SD from separate experiment.
∗∗P <. 01 for IL-1b
treatment versus the control.
increased after stimulation with IL-1α [10]; whereas the
eﬀect of IL-1α on M-CSF expression in chondrocytes was
unclear. In this study, the expression patterns of RANKL,
M-CSF, and OPG in the chondrocytes changed without
IL-1β stimulation; in the long-term culture. In addition,
we examined the expression of RANKL, M-CSF, and OPG
after long term culture in the absence of IL-1β followed by
short-term IL-1β stimulation. As a result, OPG and RANKL
expression increased with IL-1β stimulation, whereas M-
CSF expression decreased (data not shown). We believe
that this change is related to cell diﬀerentiation. Previously,
we showed that the alkaline phosphatase activity in the
same chondrocytes increased gradually from days 7 to 28
of culture without IL-1β or IL-6 stimulation [20, 22], and
that the activity decreased signiﬁcantly from day 10 of
c u l t u r ew i t hI L - 1 β stimulation compared with control [20].
In addition, the expression of type X collagen in the same
chondrocytes increased gradually from day 14 of culture
without IL-1β, and the expression decreased signiﬁcantly on
days 21 and 28 of culture with IL-1β stimulation compared
with control (data not shown). These results suggest that
proliferatingchondrocytesdiﬀerentiategraduallyintohyper-
trophic chondrocytes in long-term culture. Therefore, our
results suggest that IL-1β not only aﬀected the expression of
RANKL, M-CSF, and OPG in chondrocytes, but may also
aﬀect the course of cell diﬀerentiation. In addition, IL-1β
showed the same eﬀect for the expression of RANKL, M-
CSF, and OPG for any culture period, while the control
value changed in the long-term culture. Therefore, these
previous studies suggest that the eﬀect of IL-1 on RANKL
expression is the same in osteoblasts and chondrocytes;
whereas the eﬀect of IL-1 on OPG and M-CSF expression
diﬀers according to cell type and IL-1 subtype. We will
examine the reason why the eﬀect of IL-1β on M-CSF
expression diﬀered between osteoblasts and chondrocytes in
the future.
To clarify the indirect participation of PGE2 on the
expression of RANKL, OPG, and M-CSF in chondrocytes,
we examined the eﬀect of IL-1β and/or celecoxib on cultured
cells. According to our results, celecoxib, a speciﬁc inhibitor
of COX-2 [24, 25], blocked the stimulatory eﬀect of IL-
1β on the expression of OPG and RANKL; whereas it
did not aﬀect the IL-1β-mediated reduction in M-CSF
expression. Previously, we found that IL-1β stimulated the
expression of the EP4 receptor via an autocrine mecha-
nism involving PGE2 production in human chondrocytes
[23]. The ﬁndings in this study also suggest that IL-1β
induces the expression of OPG and RANKL in human
chondrocytes via an autocrine mechanism that increases
PGE2 production. Sakata et al. [5] reported that the IL-
1β-induced increase in OPG levels in human periodontal
ligament cells is suppressed through the de novo synthesis of
PGE2. In contrast, Coon et al. [36] reported that the baseline
levels of RANKL and OPG expression in COX-2 knockout
osteoblasts decreased compared to wild-type osteoblasts.
Considering our results, these ﬁndings suggest that the eﬀect
of PGE2 on OPG expression may diﬀer according to cell
type.
Tanabe et al. [2] reported that conditioned medium
containing M-CSF and PGE2 produced by IL-1α-treated
osteoblasts and soluble RANKL increased TRAP staining
in RAW264.7 cells. Therefore, we conducted a similar
experiment using human chondrocytes. According to our
results, conditioned medium from IL-1β-treated chondro-
cytes decreased TRAP staining in RAW264.7 cells. These
results suggest that the function of IL-1 in the diﬀerentiation
of RAW264.7 cells via the RANK/RANKL/OPG system may
diﬀer between osteoblasts and chondrocytes.
In conclusion, our results suggest that IL-1β suppresses
the formation of osteoclast-like cells via an increase in
OPG production and a decrease in M-CSF production,
at least in part, in the human chondrocytes used in this
study, and that OPG production may increase through an
autocrine mechanism involving celecoxib-related PGs. To
reinforce this conclusion further, it is necessary to conduct
a similar experiment using various chondrocytes, such as an
established chondrocyte cell line, or other clinical specimens
in the future.
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